Impact of Rosuvastatin Treatment on HDL-Induced PKC-βII and eNOS Phosphorylation in Endothelial Cells and Its Relation to Flow-Mediated Dilatation in Patients with Chronic Heart Failure

Table 1

Clinical characteristics.

	Rosuvastatin	Placebo	value
Clinical profile
Age [years]	67 (57–72)	60 (55–73)	0.65
Male gender []	7 (78%)	5 (56%)	0.62
Characterization of CHF
Ischemic heart disease []	3 (33%)	4 (44%)	1.00
LV ejection fraction [%]	34 (24–36)	30 (30–37)	0.37
LV end diastolic diameter [mm]	64 (58–71)	59 (58–65)	0.19
VO2max [mL/min/kg]	13.7 (11.5–17.0)	16.7 (13.8–19.1)	0.18
NYHA class II/III []	4/5 (44/56%)	6/3 (67/33%)	0.64
Cardiac medication
Beta blocker []	9 (100%)	9 (100%)	n.a.
ACE inhibitor or AT II blocker []	9 (100%)	9 (100%)	n.a.
Aldosterone antagonist []	7 (78%)	6 (67%)	1.00
Other diuretics []	8 (89%)	8 (89%)	1.00
Digitalis []	1 (11%)	3 (33%)	0.24

n.a.: not applicable, median (IQR).